Gilde Healthcare Partners and Advent Venture Partners.

The Netherlands Authority for the Financial Marketplaces does not supervise the collateral raising or the entrance of the brand new shares to trading on NYSE Euronext in Amsterdam.. 5 million in new equity through a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.34 per talk about, on December 29 being the closing cost, 2011, when the shares were placed. The proceeds of the issue provides additional flexibility to help expand explore its strategic choices to secure the monetary stability of the business.The DMC indicated that the basic safety data from the first interim analysis are consistent with the known security profile of ridaforolimus, no modifications to the analysis protocol were recommended. The statement of the second interim efficacy analysis, which will be predicated on around two-thirds of the full total number of progression-free survival events in the trial, is certainly expected around the final end of the initial quarter of 2010, as previously announced.